冠動脈疾患の患者における自己効力感と投薬順守:記述的研究 (SEMACAD)
冠動脈疾患のある個人における自己効力感と投薬の遵守との関係の調査:記述的および相関研究
This descriptive study aims to examine the relationship between self-efficacy and medication adherence in individuals with coronary artery disease (CAD). The study will be conducted between March and October 2025 at Adıyaman University Training and Research Hospital with a planned sample size of 135 participants. Data will be collected using a Descriptive Information Form, the Self-Efficacy for Managing Chronic Disease Scale, and the Medication Adherence Report Scale (MARS).
調査の概要
詳細な説明
Coronary artery disease (CAD) remains one of the leading causes of death worldwide. Managing CAD requires long-term treatment adherence and lifestyle changes. Self-efficacy, which reflects an individual's belief in their ability to perform specific health behaviors, plays a key role in disease management. In CAD patients, high levels of self-efficacy have been associated with better treatment adherence, improved symptom management, and successful adoption of healthy behaviors.
This descriptive study is designed to investigate the relationship between self-efficacy and medication adherence in individuals diagnosed with CAD. The study will be carried out at Adıyaman University Training and Research Hospital between March and October 2025. The target population includes patients who have been diagnosed with CAD (e.g., angina pectoris, myocardial infarction) for at least one year and meet the inclusion criteria. Based on a power analysis using G*Power software (effect size f² = 0.15, α = 0.05, power = 0.90), the required sample size is calculated as 112. However, accounting for possible data loss or participant dropout, the final sample size is set at 135.
Data collection tools include:
Descriptive Information Form to assess demographic and clinical characteristics,
The 6-Item Self-Efficacy for Managing Chronic Disease Scale, validated in Turkish by İncirkuş and Özkan Nahcivan (Cronbach's alpha = 0.90),
Medication Adherence Report Scale (MARS), adapted to Turkish by Temeloğlu Şen et al. (Cronbach's alpha = 0.78).
The findings are expected to contribute to the literature and guide healthcare professionals, particularly nurses, in planning educational and counseling services to improve self-efficacy and medication adherence among CAD patients.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Adıyaman、トルコ(Türkiye)、02040
- Adiyaman University Training and Research Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient/inpatient clinics at Adıyaman University Training and Research Hospital. All participants must be able to communicate in Turkish, have no diagnosed mental disorder, and voluntarily agree to participate in the study.
説明
Inclusion Criteria:
- Being 18 years of age or older
Having been diagnosed with Coronary Artery Disease (angina pectoris, unstable angina, myocardial infarction) at least 1 year ago
Being followed
Being able to communicate in Turkish
Voluntarily agreeing to participate in the study
Having no diagnosed mental disorder
Exclusion Criteria:
- Having a primary diagnosis other than Coronary Artery Disease
Being unable to complete the questionnaires due to mental health problems
Providing incomplete data or withdrawing from the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:CROSS_SECTIONAL
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Coronary Artery Disease Patients
This cohort consists of individuals aged 18 and older who have been diagnosed with coronary artery disease for at least one year and are being followed in cardiology or cardiovascular surgery outpatient or inpatient clinics. Patients included are those who volunteered to participate in the study, can communicate in Turkish, and do not have any mental disorders. |
This is a descriptive, observational study. No intervention or experimental procedure was performed. Data were collected using self-administered questionnaires without influencing participant behavior or treatment. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Self-efficacy score for chronic disease management
時間枠:At the time of data collection (March 2025 - October 2025)
|
Self-efficacy levels of patients with coronary artery disease will be measured using the 6-Item Self-Efficacy Scale for Chronic Disease Management. Each item is rated from 1 to 10. The total score ranges from 6 to 60, and higher scores indicate better self-efficacy in chronic disease management. |
At the time of data collection (March 2025 - October 2025)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Medication adherence score
時間枠:At the time of data collection (March 2025 - October 2025)
|
Patients' adherence to their prescribed medication regimen will be assessed using the Medication Adherence Report Scale (MARS). The MARS scale ranges from 5 to 25, with higher scores indicating better medication adherence. |
At the time of data collection (March 2025 - October 2025)
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HKU-KAH-2025-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
This study does not plan to share individual participant data (IPD).
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。